Apogee Therapeutics released Phase 2 maintenance data for zumilokibart (APG‑777) showing durable skin and itch responses with dosing intervals of three and six months. Company‑reported endpoints included high rates of EASI‑75 maintenance at one year and a favorable safety profile versus current biologics. Analysts upgraded peak sales forecasts and flagged the compound as a potential competitor to Dupixent and Ebglyss if results replicate in larger trials. Maintenance dosing data support potential differentiation through dosing convenience and long‑interval regimens.